Determination of Zipalertinib Using LC‐ESI‐MS/MS and Application to Pharmacokinetic Study in Mice
Authors:
- 16 October 2025
- journal article
- Published by Wiley in Biomedical Chromatography
- Vol. 39 (11) , e70228
Abstract
Zipalertinib is a novel, irreversible EGFR inhibitor for the treatment of non‐small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutations. A new sensitive, specific and rapid LC‐ESI‐MS/MS method has been developed and validated to quantify zipalertinib in mouse and human dried blood spot (DBS) with filgotinib used as an internal standard (IS) in accordance with regulatory guidelines. Quantification of zipalertinib and IS were achieved by triple quad mass spectrometer operated under the multiple reaction‐monitoring mode (MRM) using positive ion scan mode and parent‐daughter mass to charge ion transition of m/z 397.2 → 326.0 and m/z 426.2 → 291.2, respectively. The linear response function of zipalertinib was determined in the concentration range from 0.741 to 1111 ng/mL (r > 0.990). No matrix effect and carry over were observed. Hematocrit did not influence DBS zipalertinib concentrations. Zipalertinib demonstrated stability under various storage conditions. This method was successfully used to study the in vitro metabolic profiles and in vivo pharmacokinetics of zipalertinib in mice. An excellent correlation was observed between DBS and plasma concentrations, indicating DBS can be used as an alternative for plasma for pharmacokinetic analysis.Keywords
This publication has 23 references indexed in Scilit:
- Dried blood spot sampling coupled with liquid chromatography-tandem mass for simultaneous quantitative analysis of multiple cardiovascular drugsJournal of Chromatography B, 2024
- Dried blood spot (DBS) analysis of synthetic cathinones by different liquid chromatography-mass spectrometry techniques and interlaboratory validation for application in forensic toxicologyMicrochemical Journal, 2024
- EGFR exon20 insertion mutations in non-small cell lung cancer: Clinical implications and recent advances in targeted therapiesCancer Treatment Reviews, 2023
- Evaluation of dried blood spots as an alternative sampling strategy for 5-fluorouracil monitoring: From method development to clinical applicationJournal of Pharmaceutical and Biomedical Analysis, 2023
- Epigenetic targeting for lung cancer treatment via CRISPR/Cas9 technologyAdvances in Cancer Biology - Metastasis, 2021
- Treatment Outcomes and Safety of Mobocertinib in Platinum-Pretreated Patients With EGFR Exon 20 Insertion–Positive Metastatic Non–Small Cell Lung CancerJAMA Oncology, 2021
- Validated LC–MS/MS method for quantitation of a selective JAK1 inhibitor, filgotinib in rat plasma, and its application to a pharmacokinetic study in ratsBiomedical Chromatography, 2020
- A phase III randomised controlled trial of erlotinib vs gefitinib in advanced non-small cell lung cancer with EGFR mutationsBritish Journal of Cancer, 2017
- Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancerNature Reviews Cancer, 2010
- Oncogenic mutant forms of EGFR: Lessons in signal transduction and targets for cancer therapyFEBS Letters, 2010